Gregory Klein Selected Research

gantenerumab

1/2022	In silico exploration of amyloid-related imaging abnormalities in the gantenerumab open-label extension trials using a semi-mechanistic model.
12/2019	Gantenerumab reduces amyloid-β plaques in patients with prodromal to moderate Alzheimer's disease: a PET substudy interim analysis.
1/2018	Correction to: A phase III randomized trial of gantenerumab in prodromal Alzheimer's disease.
12/2017	A phase III randomized trial of gantenerumab in prodromal Alzheimer's disease.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Gregory Klein Research Topics

Disease

11	Alzheimer Disease (Alzheimer's Disease) 01/2022 - 01/2016
4	Cognitive Dysfunction 01/2022 - 01/2021
4	Dementia (Dementias) 01/2022 - 01/2019
1	Edema (Dropsy) 01/2022
1	Prodromal Symptoms 01/2021
1	Neurodegenerative Diseases (Neurodegenerative Disease) 01/2021
1	Primary Progressive Aphasia 01/2020
1	Disease Progression 09/2015

Drug/Important Bio-Agent (IBA)

8	Amyloid (Amyloid Fibrils)IBA 01/2022 - 09/2015
4	gantenerumabIBA 01/2022 - 12/2017
3	Biomarkers (Surrogate Marker)IBA 01/2022 - 01/2019
3	7- (6- fluoropyridin- 3- yl)- 5H- pyrido(4,3- b)indoleIBA 01/2021 - 01/2020
1	4- (N- methylamino)- 4'- (2- (2- (2- fluoroethoxy)ethoxy)ethoxy)stilbeneIBA 01/2022
1	Amyloid beta-PeptidesIBA 01/2022
1	Apolipoproteins E (ApoE)IBA 01/2021
1	FluorineIBA 01/2021
1	florbetapirIBA 12/2019

Therapy/Procedure

1	Therapeutics 01/2022